Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
NCT ID NCT07762703
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boost the immune system's ability to fight the tumor. The study will first assess safety, then compare the combination's effectiveness against standard chemotherapy in a small group of patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BreakVax (BB-101), a personalized peptide-based cancer immunotherapy, combined with ipilimumab, pembrolizumab, chemotherapy, losartan, and aspirin
- What this could lead to
- If successful, this approach could offer a new treatment option for advanced triple-negative breast cancer, potentially improving tumor control and extending survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The treatment involves multiple drugs, which may increase the risk of side effects, and the personalized manufacturing process may not be feasible for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Miami Herbert Wertheim Cancer Institute
Miami, Florida, 33176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a new drug combo outsmart triple-negative breast cancer?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?
- Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer?